👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

Centene director Jessica Blume acquires shares worth $14,870

Published 18/12/2024, 11:38 am
CNC
-

Jessica L. Blume, a director at Centene Corp (NYSE:CNC), recently acquired 250 shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The shares were purchased at a price of $59.48 each, resulting in a total transaction value of $14,870. The purchase comes as the $29.19 billion healthcare provider trades near its 52-week low, with InvestingPro analysis indicating the stock is currently undervalued. Following this acquisition, Blume indirectly owns 250 shares through a revocable family trust, where she serves as the sole trustee.

Additionally, Blume directly holds 24,786 shares of Centene's common stock, which includes 2,916 shares of restricted stock units subject to vesting requirements. The filing also indicates that Blume possesses stock options for 20,000 shares, exercisable at $55.29 per share, with an expiration date in 2028.

In other recent news, Centene Corporation has been the subject of multiple analyst adjustments. Jefferies reconfirmed an Underperform rating due to concerns about the company's focus on the Health Insurance Exchange market and skepticism over Centene's Prescription Drug Plan margins. However, JPMorgan (NYSE:JPM) upgraded Centene to Overweight, citing the company's attractive market valuation. Truist Securities adjusted Centene's stock price target to $84, maintaining a Buy rating based on the company's long-term targets and 2025 guidance. Stephens cut Centene's stock price target from $75.00 to $73.00, retaining an Equal Weight rating, while UBS upgraded Centene's rating from Neutral to Buy, adjusting the price target to $80.00 based on the company's strong financial outlook and market position.

Centene projects total revenues ranging from $166.5 billion to $169.5 billion for 2025, with an adjusted diluted earnings per share forecast for 2025 of over $7.25, exceeding the consensus estimate of $7.05. The company also reaffirmed its 2024 adjusted diluted EPS guidance of more than $6.80.

In executive changes, Sunshine Health, part of Centene Corporation, announced the appointment of Charlene Zein as its new CEO. These are among the recent developments for Centene Corporation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.